Management of acute myeloid leukemia in elderly patients

Journal of Clinical Oncology

Volumn 17, Issue 11, 1999, Pages 3569-3576

  Hiddemann, Wolfgang ^a   Kern, Wolfgang ^a   Schoch, Claudia ^a   Fonatsch, Christa ^a   Heinecke, Achim ^a   Wörmann, Bernhard ^a   Büchner, Thomas ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IDARUBICIN; TIOGUANINE; ZORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0032751381     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.11.3569     Document Type: Article

References (48)

1. Brincker H: Estimate of overall treatment results on acute non-lymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep 69:5-11, 1985
2. Cartwright RA, Staines A: Acute leukemias: Epidemiology of hematological disease - Part I. Fleming AT, ed. Baillieries Clin Haematol 5:1-26, 1992
3. Büchner T, Urbanitz D, Hiddemann W, et al: Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): Two multicenter studies of the German AML Cooperative Group. J Clin Oncol 3:1583-1589, 1985
4. Rees JHK, Gray RG, Swirsky D, et al: Principal results of the Medical Research Council's 8th acute myeloid leukaemia trial. Lancet 2:1236-1241, 1986
5. Preisler H, Davis RB, Kirshner J, et al: Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia. A Cancer and Leukemia Group B study. Blood 69:1441-1449, 1987
6. Dillmann RO, Davis RB, Green MR, et al: A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B. Blood 78:2520-2526, 1991
7. Vogler WR, Velez-Garcia E, Weiner RS, et al: A phase III trial comparing idarubicin and daunorubicin combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study. J Clin Oncol 10:1103-1111, 1992
8. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 6:896-942, 1994
9. Büchner T, Hiddemann W, Löffler H, et al: Treatment of AML in the elderly: Full dose versus reduced dose induction treatment. Blood 86:434a, 1995 (suppl 1) (abstr)
10. Rees JHK, Gray RG, Wheatley K: Dose intensification in acute myeloid leukemia: Greater effectiveness at lower cost - Principal report of the Medical Research Council's AML9 Study. Br J Hematol 94:89-98, 1996
11. Heil G, Hoelzer D, Sanz MA, et al: A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. Blood 90:4710-4718, 1997
12. Büchner T, Hiddemann W, Löffler H, et al: Double induction strategy in AML comparing high with standard dose Ara-C: Hematotoxicity and antileukemic efficacy. Blood 84:232a, 1994 (suppl 1) (abstr)
13. Hoyle CF, de Bastos M, Wheatley K, et al: AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: Results from the MRC's 9th AML trial. Br J Haematol 72:45-53, 1989
14. Hamblin TJ: The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome. Leuk Res 16:4101-4108, 1992
15. Hassan HT, Rees JKH: Relation between age and blast cell differentiation in acute myeloid leukemia patients. Oncology 47:439-442, 1990
16. Gahn B, Haase D, Unterhalt M, et al: De novo AML with dysplastic hematopoiesis: Cytogenetic and prognostic significance. Leukemia 10:946-951, 1996
17. Schiffer CA, Lee EJ, Tomiyasu T, et al: Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia. Blood 73:263-270, 1989
18. Swansbury GJ, Lawler SD, Alimena G, et al: Long-term survival in acute myelogenous leukemia: A second follow-up of the Fourth International Workshop on Chromosomes in Leukemia. Cancer Genet Cytogenet 7:1-7, 1994
19. Dastugue N, Payen C, Lafage-Pochitaloff M, et al: Prognostic significance of karyotype in de novo acute myeloid leukemia. Leukemia 9:1491-1498, 1995
20. Leith CP, Kopecky KJ, Godwin J, et al: Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDRI) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy - A Southwest Oncology Group study. Blood 89:3323-3329, 1997
21. Büchner T, Hiddemann W, Wörmann B, et al: Therapeutic outcome in AML is mainly determined by cytogenetics, LDH in serum, early response and, in a poor risk subgroup, by intensified induction treatment. Blood 90:504a, 1997 (suppl 1) (abstr)
22. Fialkow PJ, Singer JW, Raskind WH, et al: Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 317:468-473, 1987
23. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med 332:1672-1677, 1995
24. Keating MJ, McCredie KB, Bodey GP, et al: Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP). Blood 58:584-591, 1981
25. Foon KA, Zighelboim J, Yale C, et al: Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia. Blood 58:467-470, 1981
26. Sebban C, Archimbaud E, Coiftier B, et al: Treatment of acute myeloid leukemia in elderly patients. Cancer 61:227-231, 1988
27. Latagliata R, Sgardari C, Pisani F, et al: Acute nonlymphocytic leukemia in the elderly: Results of a retrospective study. Haematologica 74:167-171, 1989
28. Baudard M, Marie JP, Cadiou M, et al: Acute myelogenous leukemia in the elderly: Retrospective study of 235 consecutive patients. Br J Haematol 86:82-91, 1994
29. MacCallum PK, Rohatiner AZS, Davis CL, et al: Mitoxantrone and cytosine arabinoside as treatment of acute myeloblastic leukemia in older patients. Ann Hematol 71:35-39, 1995
30. Taylor PRA, Reid MM, Stark NN, et al: De novo acute myeloid leukemia in patients over 55-years-old: A population based study of incidence, treatment and outcome - Northern Region Haematology Group. Leukemia 9:231-237, 1995
31. Löwenberg B, Zittoun R, Kerkhofs H, et al: On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol 7:1268-1274, 1989
32. Bishop JF, Lowenthal RM, Joshua D, et al: Etoposide in acute nonlymphocytic leukemia. Blood 75:27-32, 1990
33. Tilly H, Castaigne S, Bordessoule D, et al: Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8:272-279, 1990
34. Ruutu T, Almqvist A, Hallmann H, et al: Oral induction and consolidation of acute myeloid leukemia with etoposide, 6-thioguanine, and idarubicin (ETI) in elderly patients: A randomized comparison with 5-day TAD - Finnish Leukmia Group. Leukemia 8:11-15, 1994
35. Yates J, Glidewell O, Wiernik P, et al: Cytosine arabinoside with daunorubicin or Adriamycin for therapy of acute myeloid leukemia: A CALGB study, Blood 60:454-462, 1982
36. Kahn SB, Begg CB, Mazza JJ, et al: Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 2:865-870, 1984
37. Löwenberg B, Suciu S, Archimbaud E, et al: Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): Final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 90:2952-2961, 1997
38. Stone RM, Berg DT, Stephen LG, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous Leukemia. N Engl J Med 25:1671-1677, 1995
39. Dombret H, Chastang C, Fenaux P, et al: A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. N Engl J Med 332:1678-1683, 1995
40. Büchner T, Hiddemann W, Koenigsmann M, et al: Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy with acute myeloid leukemia at higher age or after relapse. Blood 78:1190-1197, 1991
41. Ohno R, Tomonaga M, Kobayashi T, et al: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871-877, 1990
42. Maslak PG, Weiss MA, Berman E, et al: Granulocyte colony-stimulating factor following chemotherapy in elderly patients with newly diagnosed acute myelogenous leukemia. Leukemia 10:32-39, 1996
43. Geller RB: Use of cytokines in the treatment of acute myelocytic leukemia: A critical review. J Clin Oncol 14:1371-1382, 1996
44. Moore JO, Dodge RK, Amrein PC, et al: Granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B Study 9022. Blood 89:780-788, 1997
45. Rowe JM, Liesveld JL: Hematopoietic growth factors in acute leukemia. Leukemia 11:328-341, 1997
46. Rowe JM, Andersen JW, Mazza JJ, et al: A randomized, placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457-462, 1995
47. Witz F, Sadoun A, Perrin M-C, et al: A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Blood 91:2722-2730, 1998
48. Smith TJ, Ozer H, Miller LL, et al: Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 14:1957-1960, 1996